TCRR News and Press, TCR2 Therapeutics Inc. From 05/26/21

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will participate at two upcoming conferences in ...

Today, we take an in-depth look at TCR2 Therapeutics, a small immunotherapy concern. The company recently addressed its near- and medium-term funding needs and has a couple of "shots on goal." A full investment analysis follows in the paragraphs below. For further details se...

TCR2 Therapeutics (TCRR): Q1 GAAP EPS of -$0.58 misses by $0.05.Cash, cash equivalents, and investments of $333.3M.The company projects net cash use of $100-110 million for 2021, which includes tenant improvements to the Rockville facility and  expects cash on hand to support o...

CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced financial results for the first quarter ended March 31, 2021 and...

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will participate in a fireside chat at the 7th...

CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that clinical and translational data from the dose escalation ...

Gainers: [[GLYC]] +3.5%. [[CBAY]] +2.6%. [[KPTI]] +2.6%. [[GMAB]] +2.5%. [[SYRS]] +2.4%.Losers: [[VECT]] -8.1%. [[TCRR]] -2.4%. [[JFIN]] -2.3%. [[CENX]] -2.2%. [[GURE]] -1.8%. For further details see: KPTI, CENX, GMAB and TCRR among after-hours movers

CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR 2 Therape...

TCR2 Therapeutics (TCRR)  announces that it has signed a long-term, full-building lease with Alexandria Real Estate Equities (ARE) for an existing 85,000 square foot cell therapy manufacturing facility in Rockville, Maryland which is ready for Current Good Manufacturi...

85,000 square foot state-of-the-art facility being built in Rockville, Maryland Accelerates TCR 2 ’s commercial-scale manufacturing timelines with production anticipated in 2023 Aaron Vernon hired as Vice President of Technical Operations CAMBRIDGE, Mass., March...